Amphastar Pharmaceuticals (AMPH) Non Operating Interest Expenses (2013 - 2026)

Amphastar Pharmaceuticals has reported Non Operating Interest Expenses for 14 years, with the latest figure at $6.7 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 6.02% year-over-year to $6.7 million in Q2 2026; TTM through Jun 2026 was $26.1 million, a 1.7% increase from a year earlier, with the FY2025 full-year figure at $25.5 million, down 16.02% from the prior year.
• Non Operating Interest Expenses was $6.7 million for Q2 2026 at Amphastar Pharmaceuticals, up from $6.6 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $13.7 million in Q3 2023, with the low at $355000.0 in Q1 2022.
• Average Non Operating Interest Expenses over 5 years is $5.4 million, with a median of $6.4 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses surged 2320.85% in 2023, then sank 51.12% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $528000.0 in 2022, then jumped by 1690.91% to $9.5 million in 2023, then slumped by 32.05% to $6.4 million in 2024, then increased by 3.19% to $6.6 million in 2025, then rose by 0.44% to $6.7 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $6.7 million (Q2 2026), $6.6 million (Q1 2026), and $6.6 million (Q4 2025), per Business Quant data.